Ubs Group Ag Talaris Therapeutics, Inc. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$2.68 - $3.22 $372 - $447	139 New	139 $0
Q1 2023 May 12, 2023	SELL	$1.09 - $2.09 $3,610 - $6,922	-3,312 Reduced 29.86%	7,780 $14,000
Q4 2022 Feb 08, 2023	BUY	$0.94 - $1.64 $10,426 - $18,190	11,092 New	11,092 $11,000
Q2 2022 Aug 10, 2022	BUY	$4.51 - $9.85 $3,720 - $8,126	825 New	825 $4,000
Q1 2022 May 16, 2022	SELL	$6.89 - $16.56 $55,898 - $134,351	-8,113 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$12.18 - $17.0 $9,305 - $12,988	764 Added 10.4%	8,113 $124,000
Q3 2021 Nov 15, 2021	BUY	$11.61 - $15.99 $19,249 - $26,511	1,658 Added 29.13%	7,349 $100,000
Q2 2021 Aug 13, 2021	BUY	$12.25 - $18.61 $69,714 - $105,909	5,691 New	5,691 $84,000

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.